SCHEMBL5489334

SCHEMBL5489334

CCN(CC)CCCNc1ncc2cc(-c3cc(C(N)=O)ccc3C)ccc2n1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LCK P06239 12/20 0.51
KDR P35968 12/20 0.51
MAPK14 Q16539 12/20 0.51
MAPK9 P45984 2/20 0.51
MAPK10 P53779 2/20 0.51
KIT P10721 1/20 0.51
FGFR4 P22455 2/20 0.50
RIPK1 Q13546 1/20 0.49
RIPK3 Q9Y572 1/20 0.49
FGFR1 P11362 3/20 0.48
JAK3 P52333 8/20 0.47
ABL1 P00519 1/20 0.46
SRC P12931 1/20 0.45
TYK2 P29597 1/20 0.45
SYK P43405 1/20 0.45
MAPK8 P45983 1/20 0.45
BTK Q06187 1/20 0.45
BRAF P15056 2/20 0.44
TEK Q02763 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5501670 0.87 LCK (0.53) LCKKDRMAPK14MAPK9MAPK10
SCHEMBL14568935 0.85 FGFR1 (0.54) LCKKDRMAPK14MAPK9MAPK10
SCHEMBL5496704 0.84 LCK (0.49) LCKKDRMAPK14MAPK9MAPK10
SCHEMBL14569051 0.82 FGFR1 (0.57) LCKKDRMAPK14FGFR4RIPK1
SCHEMBL5495687 0.81 MAPK14 (0.70) LCKKDRMAPK14MAPK9MAPK10
SCHEMBL5490511 0.81 LCK (0.61) LCKKDRMAPK14MAPK9MAPK10
SCHEMBL5498317 0.81 LCK (0.74) LCKKDRMAPK14MAPK9MAPK10
SCHEMBL5497210 0.81 MAPK14 (0.72) LCKKDRMAPK14MAPK9MAPK10
SCHEMBL5496196 0.80 LCK (0.74) LCKKDRMAPK14MAPK9MAPK10
SCHEMBL5495660 0.80 LCK (0.74) LCKKDRMAPK14MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 LCK 106/4885KDR 1044/4885MAPK14 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.